REDACTED COPY —CONFIDENTIAL TREATMENT REQUESTED
Redacted portions have been marked with brackets containing asterisks ([***]). The redacted portions are
subject to a request for confidential treatment and have been filed separately with the Securities and Exchange
COLLABORATION AND LICENSE AGREEMENT
THIS Collaboration and License Agreement (“ Agreement ”) is made effective as of February 9, 2007
(the “ Effective Date ”) by and among SELECT Vaccines Limited, ABN 25 062 063 692, a company
incorporated under the laws of Victoria, Australia having its principal place of business at Suite 15, 545 St Kilda
Road, Melbourne, Victoria 3004, Australia (“ SVL ”), and Hepgenics Pty Ltd, ABN 44 104 360 714, a wholly
owned subsidiary of SELECT VACCINES, a company incorporated under the laws of Victoria, Australia
having its principal place of business at Suite 15, 545 St Kilda Road, Melbourne, Victoria 3004, Australia
(together with SELECT VACCINES, “ SELECT ”), and AVANT Immunotherapeutics, Inc., a Delaware
corporation having a principal place of business located at 119 Fourth Avenue, Needham, Massachusetts
02494-2725 USA (“ AVANT ”). SELECT and AVANT are each hereafter referred to individually as a “Party”
and together as “Parties”.
A. SELECT and AVANT desire to collaborate in the discovery and development of vaccines against
certain disease targets, whereby SELECT will use its virus-like particle technologies to generate and characterize
such vaccines and AVANT will use its expertise with respect to vaccines.
B. AVANT wishes to obtain from SELECT a license to the Licensed Subject Matter (hereinafter
defined) and resulting discoveries on the terms set forth herein.
C. SELECT and AVANT desire to initiate the performance of the above-described activities by
SELECT and AVANT and therefore agree to undertake the foregoing, all under the terms and conditions set
forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual covenants and premises contained below,